Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bevacizumab + fluorouracil + leucovorin + oxaliplatin + irinotecan
- Development stage
- Unknown
- Lead developer
- Yonsei University
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
A-FOLFOX + A-FOLFIRI is a combination chemotherapy regimen used as a comparator arm in clinical trials for metastatic colorectal cancer, specifically for right-sided tumors. The regimen involves the administration of the anti-VEGF monoclonal antibody bevacizumab (Avastin) in conjunction with one of two standard doublet chemotherapy backbones: FOLFOX (infusional fluorouracil, leucovorin, and oxaliplatin) or FOLFIRI (infusional fluorouracil, leucovorin, and irinotecan). Bevacizumab functions by binding to vascular endothelial growth factor A (VEGF-A), thereby inhibiting tumor angiogenesis. The chemotherapy components act as cytotoxic agents: fluorouracil inhibits thymidylate synthase, leucovorin enhances fluorouracil activity, oxaliplatin causes DNA cross-linking, and irinotecan inhibits topoisomerase I. This treatment strategy is evaluated as a first-line therapy in patients with unresectable metastatic disease.
- Other names
- A-FOLFOX + A-FOLFIRIbevacizumab plus FOLFOX or FOLFIRI
02
Targets
Beyond the preview
Go deeper on bevacizumab + fluorouracil + leucovorin + oxaliplatin + irinotecan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bevacizumab + fluorouracil + leucovorin + oxaliplatin + irinotecan.